MedPath

MERZ PHARMACEUTICALS GMBH

MERZ PHARMACEUTICALS GMBH logo
🇺🇸United States
Ownership
Subsidiary
Established
1908-01-01
Employees
101
Market Cap
-
Website
https://www.radiesse.de

Clinical Trials

176

Active:105
Completed:62

Trial Phases

5 Phases

Phase 1:56
Phase 2:12
Phase 3:36
+2 more phases

Drug Approvals

32

CIMA_AEMPS:14
NMPA:6
CANADA:4
+2 more agencies

Drug Approvals

Botulinum Toxin Type A for Injection

Product Name
注射用A型肉毒毒素
Approval Number
国药准字SJ20240011
Approval Date
Feb 23, 2024
NMPA

Botulinum Toxin Type A for Injection

Product Name
注射用A型肉毒毒素
Approval Number
国药准字SJ20240010
Approval Date
Feb 23, 2024
NMPA

Ornithine Aspartate Injection

Product Name
雅博司
Approval Number
国药准字HJ20130430
Approval Date
Jul 3, 2023
NMPA

Compound Heparin Sodium and Allantoin Gel

Product Name
康瑞保
Approval Number
国药准字HJ20181229
Approval Date
Dec 1, 2020
NMPA

Compound Heparin Sodium and Allantoin Gel

Product Name
康瑞保
Approval Number
国药准字HJ20150555
Approval Date
Dec 1, 2020
NMPA

Ornithine Aspartate Injection

Product Name
雅博司
Approval Number
H20130430
Approval Date
Nov 12, 2018
NMPA

Clinical Trials

Distribution across different clinical trial phases (113 trials with phase data)• Click on a phase to view related trials

Phase 1
56 (49.6%)
Phase 3
36 (31.9%)
Phase 2
12 (10.6%)
Phase 4
7 (6.2%)
Not Applicable
2 (1.8%)

A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

Phase 1
Completed
Conditions
N/A, as no Specific Medical Condition Will be Treated
Interventions
First Posted Date
2022-10-18
Last Posted Date
2023-06-22
Lead Sponsor
Merz Pharmaceuticals GmbH
Target Recruit Count
40
Registration Number
NCT05585398
Locations
🇩🇪

Merz Investigational Site #0490385, Hamburg, Germany

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

Phase 2
Completed
Conditions
Essential Tremor of the Upper Limb
Interventions
Drug: Placebo
First Posted Date
2021-02-23
Last Posted Date
2024-04-22
Lead Sponsor
Merz Pharmaceuticals GmbH
Target Recruit Count
78
Registration Number
NCT04766723
Locations
🇺🇸

USF, Department of Neurology, Merz Investigational Site #0010020, Tampa, Florida, United States

🇺🇸

University of Nebraska Medical Center, Merz Investigational Site #0010269, Omaha, Nebraska, United States

🇺🇸

Cleveland Clinic Lou Ruvo Center for Brain Health, Merz Investigational Site #0010457, Las Vegas, Nevada, United States

and more 11 locations

Post-Market Clinical Follow-up Performance and Safety Study of Etermis 3 and 4 in the Face

Completed
Conditions
Facial Volume Enhancement
Correction of Facial Wrinkles/Folds
First Posted Date
2019-12-24
Last Posted Date
2020-01-02
Lead Sponsor
Merz Pharmaceuticals GmbH
Target Recruit Count
154
Registration Number
NCT04210258
Locations
🇩🇪

Merz Investigational Site #0490099, Darmstadt, Germany

🇩🇪

Merz Investigational Site #0490095, Hamburg, Germany

🇩🇪

Merz Investigational Site #0490345, Hamburg, Germany

and more 3 locations

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

Phase 3
Active, not recruiting
Conditions
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Interventions
Drug: Placebo
First Posted Date
2019-06-20
Last Posted Date
2025-07-24
Lead Sponsor
Merz Pharmaceuticals GmbH
Target Recruit Count
603
Registration Number
NCT03992404
Locations
🇺🇸

Physical Medicine and Rehabilitation at University of Alabama at Birmingham; Merz investigational site #0010479, Birmingham, Alabama, United States

🇺🇸

University of Arkansas for Medical Sciences, Merz investigational site #0010481, Little Rock, Arkansas, United States

🇺🇸

Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center; Merz investigational site #0010184, Downey, California, United States

and more 68 locations

Local Study of Akatinol Memantine in VaD in Russia

Phase 3
Completed
Conditions
Vascular Dementia
Interventions
First Posted Date
2019-06-14
Last Posted Date
2022-07-22
Lead Sponsor
Merz Pharmaceuticals GmbH
Target Recruit Count
130
Registration Number
NCT03986424
Locations
🇷🇺

Federal State Budgetary Scientific Institution "Mental Health Research Center", Moscow, Russian Federation

🇷🇺

Federal State Autonomous Institution of Higher Learning "Peoples' Friendship University of Russia", Medical Institute, Moscow, Russian Federation

🇷🇺

Scientific Research Institute of Neurology, Merz Investigational Site #0070008, Moscow, Russian Federation

and more 1 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 13
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.